- Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
- Collegium to Participate in Jefferies Global Healthcare Conference
- Collegium Announces $35 Million Accelerated Share Repurchase Program
- Collegium Reports First Quarter 2024 Financial Results
- Collegium Announces CEO Transition
- Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
- Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
- Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
- Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
More ▼
Key statistics
On Monday, Collegium Pharmaceutical Inc (COLL:NSQ) closed at 33.30, -18.68% below its 52-week high of 40.95, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.65 |
---|---|
High | 33.43 |
Low | 32.48 |
Bid | 32.59 |
Offer | 34.06 |
Previous close | 32.36 |
Average volume | 349.93k |
---|---|
Shares outstanding | 32.72m |
Free float | 32.23m |
P/E (TTM) | 15.51 |
Market cap | 1.04bn USD |
EPS (TTM) | 2.06 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼